Sign In
Last checked at 
14 Aug 2017 07:00
ECO Animal Health Group plc(AIM: EAH)
ECO RECEIVES TURKISH MARKETING AUTHORISATION FOR AIVLOSIN® FOR CHICKENS LAYING EGGS FOR HUMAN CONSUMPTION
ECO Animal Health Group plc is pleased to announce that its subsidiary ECO Animal Health Limited (ECO) has received a marketing authorisation from the General Directorate of Food and Control of the Ministry of Food, Agriculture and Livestock of Turkey for the use of Aivlosin® 625 mg/g water soluble granules in chickens laying eggs for human consumption.
This approval allows ECO to start selling Aivlosin® in Turkey for the medication of drinking water for the treatment of infections caused by Mycoplasma in poultry laying eggs for human consumption, with a zero day drug withdrawal period for eggs.
ECO has begun the process of submitting the EU approved Aivlosin® regulatory files for the treatment of layers in numerous other key egg producing markets.
Aivlosin®, ECO’s patented antimicrobial, is used under veterinary prescription for the treatment of a variety of economically important respiratory and enteric (gut) diseases in poultry and pigs.
Peter Lawrence, Chairman of ECO, commented “Turkey is ranked as a global top ten egg producing country and exports eggs to both EU member countries and to the Middle East. This latest approval is another important step in the development of Aivlosin® for commercial layers and demonstrates ECO’s continued progress to becoming a major force in the international market for veterinary pharmaceutical products for livestock.”
This announcement contains inside information.
Contacts:
ECO Animal Health Group plc
| Peter Lawrence | 020 8336 6190 | ||
| Marc Loomes | 020 8447 6906 | ||
| Spiro Financial | |||
| Anthony Spiro | 020 8336 6196 | ||
| Peel Hunt LLP (Nominated Adviser) | |||
| Dan Webster, Adrian Trimmings, George Sellar | 020 7418 8900 | ||
| N+1 Singer (Joint Broker) | 020 7496 3000 | ||
| Mark Taylor, Brough Ransom | |||
ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for animals. Our products for these global growth markets promote well-being. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders
View source version on businesswire.com: http://www.businesswire.com/news/home/20170813005025/en/
Copyright Business Wire 2017
Follow the stocks
